Literature DB >> 19416156

Degradation of relaxin family peptides by insulin-degrading enzyme.

Robert G Bennett1, Dean G Heimann, Frederick G Hamel.   

Abstract

Insulin-degrading enzyme (IDE) is a ubiquitously expressed metalloproteinase responsible for the intracellular degradation of insulin. IDE also interacts with other members of the insulin superfamily, including relaxin, but no studies have been reported regarding the interaction of other relaxin-like peptides with IDE. In this study, we determined that relaxin, relaxin-3, and InsL3 all competitively inhibited the degradation of insulin by IDE to different degrees, and all inhibited covalent cross-linking of insulin to IDE. Each of the peptides was degraded by IDE to various degrees (insulin > relaxin > InsL3 = relaxin-3). In summary, relaxin, InsL3, and relaxin-3 all bound to IDE, competed for the binding and degradation of insulin, and were all substrates for the proteolytic activity of IDE. Therefore, it is possible that in addition to insulin, IDE may be important for the cellular proteolysis of relaxin, InsL3, and relaxin-3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416156      PMCID: PMC2708001          DOI: 10.1111/j.1749-6632.2008.03782.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

Authors:  K Vekrellis; Z Ye; W Q Qiu; D Walsh; D Hartley; V Chesneau; M R Rosner; D J Selkoe
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

2.  Characterization of the binding of 125I-relaxin to rat uterus.

Authors:  R C Mercado-Simmen; G D Bryant-Greenwood; F C Greenwood
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

3.  Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats.

Authors:  H Fakhrai-Rad; A Nikoshkov; A Kamel; M Fernström; J R Zierath; S Norgren; H Luthman; J Galli
Journal:  Hum Mol Genet       Date:  2000-09-01       Impact factor: 6.150

4.  Degradation of amylin by insulin-degrading enzyme.

Authors:  R G Bennett; W C Duckworth; F G Hamel
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

5.  Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.

Authors:  Bonnie C Miller; Elizabeth A Eckman; Kumar Sambamurti; Nicole Dobbs; K Martin Chow; Christopher B Eckman; Louis B Hersh; Dwain L Thiele
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

Review 6.  Insulin degradation: progress and potential.

Authors:  W C Duckworth; R G Bennett; F G Hamel
Journal:  Endocr Rev       Date:  1998-10       Impact factor: 19.871

7.  Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.

Authors:  W Q Qiu; D M Walsh; Z Ye; K Vekrellis; J Zhang; M B Podlisny; M R Rosner; A Safavi; L B Hersh; D J Selkoe
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

8.  Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme.

Authors:  R G Bennett; J Fawcett; M C Kruer; W C Duckworth; F G Hamel
Journal:  J Endocrinol       Date:  2003-06       Impact factor: 4.286

9.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

10.  Inhibition of insulin degradation by insulin-like growth factors.

Authors:  R I Misbin; E C Almira; W C Duckworth; T D Mehl
Journal:  Endocrinology       Date:  1983-10       Impact factor: 4.736

View more
  7 in total

1.  An angiotensin-(1-7) peptidase in the kidney cortex, proximal tubules, and human HK-2 epithelial cells that is distinct from insulin-degrading enzyme.

Authors:  Bryan A Wilson; Nildris Cruz-Diaz; Allyson C Marshall; Nancy T Pirro; Yixin Su; TanYa M Gwathmey; James C Rose; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-07

2.  Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.

Authors:  Zhanna Kobalava; Svetlana Villevalde; Yulia Kotovskaya; Holger Hinrichsen; Marc Petersen-Sylla; Andreas Zaehringer; Yinuo Pang; Iris Rajman; Jasna Canadi; Marion Dahlke; Peter Lloyd; Atef Halabi
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

3.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

4.  Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.

Authors:  Qingxue Li; Mir A Ali; Kening Wang; Dean Sayre; Frederick G Hamel; Elizabeth R Fischer; Robert G Bennett; Jeffrey I Cohen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

5.  Protective Role of Testicular Hormone INSL3 From Atrophy and Weakness in Skeletal Muscle.

Authors:  Alberto Ferlin; Luca De Toni; Alexander I Agoulnik; Giorgia Lunardon; Andrea Armani; Sergia Bortolanza; Bert Blaauw; Marco Sandri; Carlo Foresta
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-28       Impact factor: 5.555

6.  Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.

Authors:  Marion Dahlke; Atef Halabi; Jasna Canadi; Chiaki Tsubouchi; Surendra Machineni; Yinuo Pang
Journal:  J Clin Pharmacol       Date:  2015-11-04       Impact factor: 3.126

7.  Comparative Distribution of Relaxin-3 Inputs and Calcium-Binding Protein-Positive Neurons in Rat Amygdala.

Authors:  Fabio N Santos; Celia W Pereira; Ana M Sánchez-Pérez; Marcos Otero-García; Sherie Ma; Andrew L Gundlach; Francisco E Olucha-Bordonau
Journal:  Front Neuroanat       Date:  2016-04-07       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.